Vascular Mediation of Site-Specific BMD Response to Osteoanabolic Drugs

confidence: high · 1 sources

⚠
Working research — not a recommendation.

This page records what the evidence says a policy does, not what anyone should do about it. It has been synthesized from the cited sources but has not been independently reviewed.

What the evidence says

The sources on this page come from one review, Marenzana (2013), which covers how blood vessels may mediate the bone-building action of parathyroid hormone (PTH). They describe one lever, PTH, and one vascular pathway: dilation of bone blood vessels, driven partly by VEGF and by nitric oxide (NO).

PTH-induced relaxation of bone blood vessels, measured ex vivo, has been linked with PTH's osteoanabolic activity. The link is associational. The claims do not say whether vasodilation causes the bone gain or both share a common cause.

The causal evidence comes from blocking the pathway in animals. In mice, an inhibitor of NO synthase (L-NAME) blocked PTH's vasorelaxant effect and partially blunted its osteoanabolic action. "Partially" is the only magnitude given. The claims give no percentage. Blocking VEGF also blunted the bone mass accrual induced by intermittent PTH in mice, again without a stated size. A study by Prisby and colleagues showed that PTH dilated bone arteries and that VEGF partly mediated the dilation. So VEGF is one of the mediators, and the claims do not say whether others exist.

A separate line of evidence covers NO donors, such as nitroglycerine and isosorbide mononitrate. The review reports strong evidence that they increase bone mass in animals and in osteoporotic patients. It also notes some conflicting human studies.

Gaps: the claims give no effect sizes for any of these findings. They also give no site-specific BMD comparison, for example spine versus hip or cortical versus trabecular bone. The topic asks about site-specific response, and these sources do not address it. Nor do they cover osteoanabolic drugs other than PTH.

Where the evidence splits

The NO donor finding contains a split. The review reports increased bone mass in animals and osteoporotic patients, but "some conflicting studies in humans." The sources on this page do not say what design, population, or dose difference explains the conflicting human results, so the split is unexplained by the sources on this page.

Thresholds and dose-response

No threshold established in the current sources.

Open empirical questions

Findings

PTH-induced vasodilation in bone blood vessels is associated with increased bone formation

confidence — direction: highconfidence — magnitude: mediumconsensus: thin. The claim comes from one review citing experimental studies.
mechanism
vasodilation of bone blood vessels is proposed as part of PTH's osteoanabolic action. The claim is associational and does not establish causation.
effect
direction is an association between vasorelaxation (ex vivo) and osteoanabolic activity. No magnitude is given.
conditions / moderators
not established. The claims do not say whether the link reflects causation or confounding.

Blocking NO synthesis decreases PTH-induced bone formation in mice

confidence — direction: highconfidence — magnitude: mediumconsensus: thin. One review reports the result.
mechanism
PTH relaxes bone blood vessels through NO. The NO synthase inhibitor L-NAME blocks this vasorelaxant effect.
effect
decreases PTH's osteoanabolic action. The review calls the reduction partial. No percentage is given.
conditions / moderators
shown in mice. Not established in humans.

Blocking VEGF decreases bone mass accrual from intermittent PTH in mice

confidence — direction: highconfidence — magnitude: mediumconsensus: thin. One review reports the result.
mechanism
PTH dilates bone arteries partly through VEGF. Blocking VEGF removes part of that pathway.
effect
decreases the osteogenic effect of intermittent PTH. The review says it was "blunted." No magnitude is given.
conditions / moderators
shown in mice. The claims do not say whether VEGF is the sole mediator or one of several. The review says it partly mediates the arterial dilation.

PTH increases dilation of bone arteries, partly through VEGF

confidence — direction: highconfidence — magnitude: mediumconsensus: thin. The claim rests on one cited study (Prisby and colleagues), as described in one review.
mechanism
VEGF mediates part of PTH's vasodilatory effect on bone arteries.
effect
increases bone artery dilation. No magnitude is given.
conditions / moderators
not established. The claims do not say whether other mediators contribute.

NO donor supplementation increases bone mass in animals and osteoporotic patients

confidence — direction: highconfidence — magnitude: mediumconsensus: contested in humans. The weight leans toward an increase, with some conflicting human studies.
mechanism
NO donors supply nitric oxide. NO is the same signal PTH uses to dilate bone vessels.
effect
increases bone mass. No magnitude is given.
conditions / moderators
the review notes some conflicting studies in humans. The sources here do not explain why.